FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085584881> ?p ?o ?g. }

• W3085584881 abstract "Abstract Potent protection against malaria can be induced by attenuated live-immunization with Plasmodium falciparum (Pf) sporozoites (SPZ). However, a better understanding of the critical processes involved in the establishment of protective immunity is needed. We explored the safety and vaccine efficacy of early chemo-attenuation of PfSPZ under atovaquone-proguanil (AP). AP caused early arrest of P. berghei liver stages. Despite the absence of replication, robust protection in mice correlated with parasite-specific effector-memory CD8 + T-cell responses. In a phase I clinical trial a single dose of AP prevented Pf infections in the liver of adult, human subjects who received three doses of 5.12x10 4 or 1.5x10 5 PfSPZ by direct venous inoculation combined with oral AP. However, only 2 of 8 (25%) and 2 of 10 (20%), respectively, were protected against controlled human malaria infection (CHMI) 10 weeks after the last vaccine dose, despite levels of IgG antibodies to the Pf circumsporozoite protein (PfCSP) comparable to those achieved in fully protected volunteers after immunization with 5.12x10 4 PfSPZ with chloroquine chemoprophylaxis active only against subsequent blood stages. We identify lower IgG recognition of the secreted liver stage-specific antigens LISP2 and LSA1 and the multi-stage antigen MSP5 as immune signatures of inferior vaccine efficacy compared to PfSPZ with chloroquine chemoprophylaxis. In conclusion, we show that immune signatures of liver stage antigens, but neither an established rodent malaria model nor concentrations of antibodies against the major surface protein of sporozoites, permit prediction of vaccine efficacy. Thus, this study provides a clear rationale for the development of live sporozoite vaccination protocols that boost exposure to Pf liver stage antigens. Significance Statement Our research demonstrates that attenuation of liver infection of high doses of Plasmodium falciparum sporozoites by concomitant single-dose administration of atovaquone-proguanil is safe in humans. However, vaccine efficacy was modest when compared to an identical protocol using chloroquine that acts only on the subsequent blood infection. Immune signatures of secreted P. falciparum liver stage antigens, but neither an established rodent malaria model nor concentrations of sporozoite antibodies, permit prediction of vaccine efficacy." @default.
• W3085584881 created "2020-09-21" @default.
• W3085584881 creator A5000062936 @default.
• W3085584881 creator A5000295555 @default.
• W3085584881 creator A5001355322 @default.
• W3085584881 creator A5002924766 @default.
• W3085584881 creator A5007872775 @default.
• W3085584881 creator A5008912785 @default.
• W3085584881 creator A5014089835 @default.
• W3085584881 creator A5016638746 @default.
• W3085584881 creator A5018889173 @default.
• W3085584881 creator A5021511716 @default.
• W3085584881 creator A5022856467 @default.
• W3085584881 creator A5026404259 @default.
• W3085584881 creator A5029210823 @default.
• W3085584881 creator A5029756286 @default.
• W3085584881 creator A5035148816 @default.
• W3085584881 creator A5036246322 @default.
• W3085584881 creator A5036392739 @default.
• W3085584881 creator A5038195746 @default.
• W3085584881 creator A5042890936 @default.
• W3085584881 creator A5043369631 @default.
• W3085584881 creator A5050755743 @default.
• W3085584881 creator A5054982693 @default.
• W3085584881 creator A5059624566 @default.
• W3085584881 creator A5063335396 @default.
• W3085584881 creator A5067621342 @default.
• W3085584881 creator A5069444301 @default.
• W3085584881 creator A5069824378 @default.
• W3085584881 creator A5070489719 @default.
• W3085584881 creator A5071673766 @default.
• W3085584881 creator A5073416570 @default.
• W3085584881 creator A5073651555 @default.
• W3085584881 creator A5080350850 @default.
• W3085584881 creator A5080619120 @default.
• W3085584881 creator A5084698727 @default.
• W3085584881 creator A5087910015 @default.
• W3085584881 creator A5090201395 @default.
• W3085584881 creator A5090639293 @default.
• W3085584881 creator A5090885081 @default.
• W3085584881 date "2020-09-14" @default.
• W3085584881 modified "2023-10-12" @default.
• W3085584881 title "Mapping of safe and early chemo-attenuated live<i>Plasmodium falciparum</i>immunization identifies immune signature of vaccine efficacy" @default.
• W3085584881 cites W1242484266 @default.
• W3085584881 cites W1527871699 @default.
• W3085584881 cites W1902761939 @default.
• W3085584881 cites W1972073650 @default.
• W3085584881 cites W1979427692 @default.
• W3085584881 cites W1987858349 @default.
• W3085584881 cites W2000920812 @default.
• W3085584881 cites W2010412870 @default.
• W3085584881 cites W2012497305 @default.
• W3085584881 cites W2029458153 @default.
• W3085584881 cites W2030713521 @default.
• W3085584881 cites W2035645815 @default.
• W3085584881 cites W2039481952 @default.
• W3085584881 cites W2044250136 @default.
• W3085584881 cites W2060564531 @default.
• W3085584881 cites W2063903553 @default.
• W3085584881 cites W2066593591 @default.
• W3085584881 cites W2067517994 @default.
• W3085584881 cites W2068125083 @default.
• W3085584881 cites W2085737842 @default.
• W3085584881 cites W2091008751 @default.
• W3085584881 cites W2101936936 @default.
• W3085584881 cites W2106840507 @default.
• W3085584881 cites W2119855808 @default.
• W3085584881 cites W2122409545 @default.
• W3085584881 cites W2128435044 @default.
• W3085584881 cites W2137788412 @default.
• W3085584881 cites W2138840836 @default.
• W3085584881 cites W2139668262 @default.
• W3085584881 cites W2144296388 @default.
• W3085584881 cites W2153080484 @default.
• W3085584881 cites W2154128809 @default.
• W3085584881 cites W2157408260 @default.
• W3085584881 cites W2169790609 @default.
• W3085584881 cites W2170265923 @default.
• W3085584881 cites W2211385524 @default.
• W3085584881 cites W2234108055 @default.
• W3085584881 cites W2315650975 @default.
• W3085584881 cites W2346928357 @default.
• W3085584881 cites W2436574078 @default.
• W3085584881 cites W2587907012 @default.
• W3085584881 cites W2588256621 @default.
• W3085584881 cites W2591439676 @default.
• W3085584881 cites W2604393158 @default.
• W3085584881 cites W2612412535 @default.
• W3085584881 cites W2804552758 @default.
• W3085584881 cites W4254848468 @default.
• W3085584881 doi "https://doi.org/10.1101/2020.09.14.296152" @default.
• W3085584881 hasPublicationYear "2020" @default.
• W3085584881 type Work @default.
• W3085584881 sameAs 3085584881 @default.
• W3085584881 citedByCount "7" @default.
• W3085584881 countsByYear W30855848812020 @default.
• W3085584881 countsByYear W30855848812021 @default.
• W3085584881 countsByYear W30855848812022 @default.
• W3085584881 countsByYear W30855848812023 @default.
• W3085584881 crossrefType "posted-content" @default.

• next